leisure time -WSS

leisure time

author：explore 2025-09-28 14:50:00 - browse：77

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Bird flu in milk supply is likely coming from asymptomatic cows

Wikipedia

focus

WSS

Redefining sustainability for the pharmaceutical industry

Change Healthcare cyberattack shows risk of industry consolidation

H5N1 bird flu found in pasteurized milk: what we know

Exact Sciences stock tumbles despite strong cancer detection sales

Laying a path for careers in science

Elisabeth Bik tackles the widespread issue of research misconduct

focus

leisure time

focus

Affirmative action in medical school literally saved lives

Color Health wants to make cancer screenings convenient

What does generative AI mean for health care? We asked experts

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Tori Bowie and the unacceptable rates of Black maternal death

Color Health wants to make cancer screenings convenient

Guidelines to prevent youth baseball injuries need more muscle

Are embryos people? Reproductive medicine's future depends on the answer

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Exact Sciences stock tumbles despite strong cancer detection sales

hotspot

Cholera vaccine supply gets boost as demand surges globally

Melinda French Gates resigns from Gates Foundation

Study fuels hope CAR

Medicare Advantage isn’t working — for anyone

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

STAT Madness 2024: Meet the contenders

focus

Wikipedia

focus

entertainment